Evidence map›Paper›PMID 41343028›Full record

ReviewNeuromolecular medicine2025

Targeting Microglial Activation to Modulate Neuroinflammation in Alzheimer's Disease.

Vinay Patil, Amit Sharma, Bhavin Parekh, Husni Farah, S Renuka Jyothi, Swati Mishra, Anima Nanda, Shaker Al-Hasnaawei, Manoj Kumar Mishra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. New Oligophenalenone Dimers fromMolecules (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vinay PatilArnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY, 11201, USA.
Amit SharmaArnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY, 11201, USA.
Bhavin ParekhArnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY, 11201, USA.
Husni FarahFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
S Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Swati MishraDepartment of Pharmacology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, 751003, Odisha, India.
Anima NandaDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Shaker Al-HasnaaweiCollege of Pharmacy, the Islamic University, Najaf, Iraq.
Manoj Kumar MishraCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. biopolymer714@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease is a multifaceted neurodegenerative condition marked by the build-up of amyloid plaques and neurofibrillary tangles that lead to progressive cognitive impairment. Neuroinflammation, especially the activation of microglia, plays a pivotal part in driving this pathology. Microglia are the brain's resident immune cells and can adopt a spectrum of activation states that support either neuroprotection or neurodegeneration. Evidence shows that their phenotypes are highly dynamic and shaped by environmental influences and pathological signals. During the early phases of the disease, microglia tend to assume anti-inflammatory roles that facilitate plaque clearance and promote tissue recovery. Prolonged or dysregulated activation, however, shifts them toward a pro-inflammatory state that amplifies neuronal damage. Several molecular pathways including JAK STAT, PI3K AKT, and MAPK are central to regulating these processes and have emerged as promising therapeutic targets. This review summarizes current insights into microglial phenotypic transitions, the signaling mechanisms governing their activation, and the therapeutic potential of modulating neuroinflammation. Enhancing the neuroprotective capacity of microglia, suppressing chronic inflammatory responses, and targeting key receptors such as TREM2 and P2 × 7 represent potential strategies. A deeper understanding of microglial interactions with other glial cells and the molecular drivers of their activation may provide new avenues for slowing or halting the progression of Alzheimer's disease and related neurodegenerative disorders.

Indexed as

Alzheimer DiseaseMicrogliaMolecular Targeted TherapyNeuroinflammatory DiseasesAmyloid beta-PeptidesAnimalsHumansMembrane GlycoproteinsNeuroprotective AgentsPlaque, AmyloidReceptors, ImmunologicSignal TransductionAmyloid beta-PeptidesMembrane GlycoproteinsNeuroprotective AgentsReceptors, ImmunologicTREM2 protein, humanAlzheimer’s diseaseMicrogliaNeurodegenerationNeuroinflammationTherapeutic strategies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.